At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia
In Brief
A Phase 2 clinical trial evaluating MMFS-202-302 and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The goals of this study are to study MMFS-202-302 in a double blind, randomized, placebo-controlled 9-week study of its effect on ameliorating cognitive deficits in 60 patients with schizophrenia or schizoaffective disorder with stable levels of positive symptoms. Secondary end points will include changes in positive and negative symptoms. One dose of MMFS-202-302 will be studied and compared with placebo as adjunctive treatment to atypical antipsychotic drug treatment.
Study Details
Timeline
Interventions
Active ingredient: L-Threonic acid Magnesium salt. 1 g (2 pills) by mouth once daily in the evening for 9 weeks Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt 1 g (2 pills) by mouth once daily in the morning for 9 weeks
Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.